Apoptosis-based drug screening and detection of selective toxicity to cancer cells

Anti-Cancer Drugs

Volumn 14, Issue 7, 2003, Pages 555-561

  Frankfurt, Oskar S ^a,b   Krishan, Awtar ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Apostain Inc   (United States)

Author keywords

Anticancer drugs; Apoptosis; Drug screening; ELISA; Selective toxicity

Indexed keywords

2,4 DINITROPHENOL; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; BENZOTHONIUM; CADMIUM CHLORIDE; CHLORPROMAZINE; CISPLATIN; CYCLOHEXEMIDE; DOXORUBICIN; ETOPOSIDE; MERCURIC CHLORIDE; MITOMYCIN C; N DIMETHYLFORMAMIDE; PACLITAXEL; QUANIDINE SULFATE; STAUROSPORINE; THIORIDAZINE; TIOGUANINE; TOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIPLOIDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; TOXINS, BIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 0042833078     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200308000-00008     Document Type: Article

References (25)

1. Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 2002; 94:78-79.
2. Dunstan HM, Ludlow C, Goehle S, Cronk M, Szankasi P, Evans RH, et al. Cell-based assays for identification of novel double-strand break-inducing agents. J Natl Cancer Inst 2002; 94:88-93.
3. Vassilev LT, Kazmer S, Marks IM, Pezzoni G, Sala F, Mischke SH, et al. Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two nover cell-cycle inhibitors. Anticancer Drug Des 2001; 16:7-17.
4. Frankfurt OS, Krishan A. Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism. Chem-Biol Interact 2003; 145:89-99.
5. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationship between drug activity in NCl preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
6. 1 phase of the cell cycle and specific-related mortality in transformed cells. J Cell Biol 1996; 135:689-700.
7. Lu J, Ho C, Ghai G, Chen Ky. Differential effects of theaflavin monogallates on cell growth, apoptesis and Cox-2 expression in cancer versus normal cell. Cancer Res 2000; 60:6465-6471.
8. Outo SS, Ng CE. Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin treatment and X-radiation treatment a human melanoma and human fibroblast cell line. Cancer Chemother Pharmacol 2002; 49:167-175.
9. Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in breast tumor cell line MDA MB 468 but not in nontumorigenic HBL 100 line. Mol Cancer Ther 2002; 1:1161-1172.
10. Woynarowska BA, Woynarowska JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochim Biophys Acta 2002; 1587:309-317.
11. Blajeski AL, Kottke TJ, Kaufmann SH. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 2001; 270:277-288.
12. Frankfurt OS, Robb JA, Sugarbaker E, Villa V. Monoclonal antibody to single-stranded DNA is a sensitive and specific cellular marker of apoptosis. Exp Cell Res 1996; 226:387-397.
13. Frankfurt OS, Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin, J Histochem Cytochem 2001; 49:369-378.
14. Frankfurt OS, Krishan A. Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J Immunol Methods 2001; 253:133-144.
15. Zamzani N, Kroemer J. Condensed matter in cell death. Nature 1999; 401:127-128.
16. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83:757-766.
17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
18. Sheers EM, Ekwal B, Dierickx PJ. In vitro long-term cytotoxicity testing of 27 MEIC chemicals on HEP 2 cells and comparison with acute human toxicity data. Toxicol In Vitro 2001; 15:153-161.
19. Evans SM, Casartelli A, Herreros E, Minnick DT, Day C, George C, et al. Development of high throughput toxicity screen predictive of high acute in vivo toxic potential. Toxicol In Vitro 2001; 15:579-584.
20. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:376-387.
21. Koornstra JJ, de Long S, Hollema H, de Vries EGE, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 2003; 45:37-53.
22. Frankfurt OS, Seckinger D, Sugarbaker EV, Villa L. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl2 expression, hormone receptors and lymph node metastases. Clinical Cancer Res 1997; 3:465-471.
23. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000; 57:503-511.
24. Mathiasen IS, Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol Med 2002; 8:212-220.
25. Alonso M, Tamasdan C, Miller DC, Newcomb EV. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway by a caspase independent pathway. Mol Cancer Ther 2003; 2:139-150.